{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:58:35Z","timestamp":1760057915403,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer","award":["P1203779"],"award-info":[{"award-number":["P1203779"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The burden of ulcerative colitis (UC) is increasing in Saudi Arabia (KSA), and patients with UC often suffer from delays in diagnosis and appropriate management. This study investigates the current UC patient journey in KSA from the healthcare professionals\u2019 (HCPs) perspective. It aims to evaluate treatment patterns, identify critical gaps, and provide insights to guide interventions that enhance the quality of life for UC patients in KSA. Methods: Quantitative interviews were conducted with 60 HCPs (45 gastroenterologists and 15 internal medicine specialists) from different regions in Saudi Arabia (KSA) using a Computer-Assisted Personal Interview (CAPI) system. The survey domains included clinical symptoms, diagnostic testing, endoscopic scoring, treatment goals, and medication sequencing. Results: Data were collected from 60 HCPs with an average of 17 \u00b1 12.5 years of experience. Most patients with UC were referred by general practitioners (28%), internal medicine physicians (25%), followed by surgeons (16%). The first-ranked treatment goals were clinical remission (53.3%), endoscopic remission (35%), and improvement of quality of life (33.3%). For outpatient moderate-to-severe UC, the most common first-line treatments are oral systemic steroids (34%), 5-aminosalicylates (5-ASAs) (26%), and TNF-\u03b1 inhibitors (21%). While second-line treatment rankings were TNF-\u03b1 inhibitors (23%), followed by Interleukin 12\/23 inhibitors (19%), and Janus kinase (JAK) inhibitors (14%). Sphingosine 1-phosphate (S1P) receptor modulators are not well-utilized due to a lack of availability (88%), unfamiliarity with the treatment (24%), and formulary exclusion (12%). Conclusions: In conclusion, most UC patients are referred by general practitioners. Treating gastroenterologists prioritize clinical remission as a treatment goal. Corticosteroids remain overutilized as reflected by treating physicians\u2019 responses. The underutilization of advanced therapies underscores the need for enhanced education and improved access to integrate emerging therapies effectively.<\/jats:p>","DOI":"10.3390\/jcm14051621","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:48:37Z","timestamp":1740710917000},"page":"1621","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the Ulcerative Colitis Patient Journey in Saudi Arabia from Healthcare Professionals\u2019 Perspective: A Cross-Sectional Non-Interventional Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Nahla","family":"Azzam","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, King Saud University, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1297","authenticated-orcid":false,"given":"Mahmoud","family":"Mosli","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, King Abdul-Aziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulelah","family":"Almutairdi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh 12271, Saudi Arabia"},{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesfer","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, AlHada Armed Force Hospital, Taif 26792, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-1921","authenticated-orcid":false,"given":"Yaser","family":"Meeralam","sequence":"additional","affiliation":[{"name":"Digestive and Liver Health and Advanced Endoscopy Center, King Abdullah Medical City, Makkah 24246, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Alolimi","sequence":"additional","affiliation":[{"name":"Pfizer, Medical Affairs, Riyadh 13519, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Arsalan","sequence":"additional","affiliation":[{"name":"Pfizer, Medical Affairs, Riyadh 13519, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh 12271, Saudi Arabia"},{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"},{"name":"Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12950-020-00246-4","article-title":"Ulcerative colitis: Understanding its cellular pathology could provide insights into novel therapies","volume":"17","author":"Kaur","year":"2020","journal-title":"J. Inflamm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","article-title":"Ulcerative colitis: Epidemiology, diagnosis, and management","volume":"89","author":"Feuerstein","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/j.sempedsurg.2017.10.003","article-title":"Clinical presentation of Crohn\u2019s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes","volume":"26","author":"Yu","year":"2017","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","article-title":"Diagnosis and classification of ulcerative colitis","volume":"13","author":"Conrad","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.14309\/ajg.0000000000000183","article-title":"A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review","volume":"114","author":"Ungaro","year":"2019","journal-title":"Off. J. Am. Coll. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and Pathogenesis of Ulcerative Colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/sjg.sjg_277_22","article-title":"Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease","volume":"29","author":"Mosli","year":"2023","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/17474124.2018.1503052","article-title":"Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East","volume":"12","author":"Sharara","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_12","unstructured":"(2024, January 01). ICH Topic E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting Step 5 NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING. Available online: https:\/\/www.ema.europa.eu\/en\/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting-scientific-guideline."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA Living Clinical Practice Guideline on Phar-macological Management of Moderate-to-Severe Ulcerative Colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Peyrin-Biroulet, L., Arkkila, P., Armuzzi, A., Danese, S., Guardiola, J., Jahnsen, J., Lees, C., Louis, E., Luk\u00e1\u0161, M., and Reinisch, W. (2022). Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02347-1"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Schreiber, S., Pan\u00e9s, J., Louis, E., Holley, D., Buch, M., and Paridaens, K. (2024, January 01). Perception Gaps Between Patients with Ulcerative Colitis and Healthcare Professionals: An Online Survey. Available online: http:\/\/www.biomedcentral.com\/1471-230X\/12\/108.","DOI":"10.1186\/1471-230X-12-108"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living with Ulcerative Colitis-Patients\u2019 and Physicians\u2019 View","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1621\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:46Z","timestamp":1760028226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051621"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051621","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}